myLaminin Perspectives

ICH E6 (R3) is reshaping clinical trial compliance across Canada, the U.S., EU, UK, and Australia. The updated Good Clinical Practice (GCP) guideline emphasizes Quality by Design, proactive risk management, audit trail traceability, sponsor oversight, informed consent, data integrity, and inspection readiness. myLaminin helps research teams and sponsors manage multi-site clinical trials with real-time oversight, CTQ monitoring, compliant eConsent, secure audit trails, and val

Multi-site clinical trials are widely used across North America to improve recruitment and accelerate timelines, but hidden operational risks often undermine success. Site variability, uneven engagement, communication breakdowns, and fragmented technology adoption create systemic inefficiencies that erode data quality and compliance. Without integrated oversight and standardized processes, complexity scales faster than control, increasing trial failure risk.

Poor clinical trial coordination drives costly delays, data integrity risks, and regulatory exposure across multi-site studies in Canada, the US, and globally. Fragmented systems, inconsistent documentation, and weak communication slow approvals, inflate Phase III costs, and erode patient trust. Integrated CTMS/CR/os platforms like myLaminin unify stakeholders, streamline workflows, strengthen compliance, and enable real-time oversight turning coordination into a competitive

Spreadsheet-driven clinical trials introduce hidden risks in compliance, data integrity, and efficiency. While Excel remains a convenient tool, it often evolves into ungoverned infrastructure, creating version control issues, audit gaps, and costly delays. Modern CTMS platforms like myLaminin help research teams reduce spreadsheet dependency, strengthen governance, and streamline workflows without sacrificing flexibility in complex, data-intensive studies.